NIH CONTRACEPTIVE DEVELOPMENT INITIATIVE PLANNED FOR FY 1986
Executive Summary
NIH CONTRACEPTIVE DEVELOPMENT INITIATIVE PLANNED FOR FY 1986 would be funded at $3.35 mil., National Institute of Child Health and Human Development Acting Director Duane Alexander told a March 27 hearing before the House Commerce/Health Subcmte. The initiative would "take advantage of some of the discoveries that are coming in from our basic reproductive sciences research programs that hold great promise for new types of contraception that will be applicable to different segments and ages of the population," Alexander said. NIH contraceptive development grant funding increased from $5.05 mil. in FY 1984 to $7.7 mil. in FY 1985, Alexander said, while funding for contraceptive evaluation increased from $2.5 mil in FY 1984 to $3.45 mil. in FY 1985. Subcmte. Chairman Waxman (D-Calif.) convened the hearing to receive testimony on reauthorization of the Public Health Service Act Title X family planning service program. In FY 1984, NIH "planned to spend over $11 mil." on contraceptive research, "but ended up spending almost 40% less than that," Waxman asserted. This was the "same year" that the congressional Office of Technology Assessment recommended that the agency spend "an additional $20 mil. on contraceptive development," he added.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth